News
Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I
Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of recurrent GBM will be presented as a
Aurinia Appoints Joe Miller as Chief Financial Officer
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Alphatec Holdings Terminates Tender Offer Agreement with EOS imaging
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) ("EOS"), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical
Premier Inc. to Report Fiscal 2020 Third-Quarter Results and Host Conference Call Before Market Opens on May 5
Premier Inc. (NASDAQ: PINC) plans to report fiscal 2020 third-quarter financial results the morning of May 5, 2020, followed by a conference call at 8 a.m. ET to discuss the results.
Conference
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 7, 2020, following the release of its first quarter
Pfizer Hosts Virtual-Only Annual Meeting of Shareholders
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent second-quarter 2020 dividend on the company’s common stock, payable June 5, 2020 to shareholders of record at the close of
Pfizer Hosts Virtual-Only Annual Meeting of Shareholders
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent second-quarter 2020 dividend on the company’s common stock, payable June 5, 2020 to shareholders of record at the close of
Humana and the National Quality Forum Publish Population Health Paper in the New England Journal of Medicine
Physician leaders from Humana Inc. (NYSE: HUM) and the National Quality Forum (NQF) explore the impact that social, behavioral and environmental factors – such as access to healthy foods, safe
Agilent Receives FDA Approval for PD-L1 Companion Diagnostic on Dako Omnis
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for
Agilent Signs Sponsorship Agreement with My Green Lab
Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific
Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced its 2019 financial